CelLBxHealth
Logotype for CelLBxHealth plc

CelLBxHealth (CLBX) investor relations material

CelLBxHealth Q3 2026 TU earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for CelLBxHealth plc
Q3 2026 TU earnings summary21 Oct, 2026

Executive summary

  • Q3 new business rose threefold YoY to £0.3m; 9M cash operating loss fell 60% to £4.0m, while FY 2026 revenue guidance was revised to ~£1.8m due to timing effects from operational realignment.

  • FY 2027 revenue is expected to reach £3.0m–£4.0m, supported by stronger commercial momentum, an expanding pipeline and operational improvements.

Financial highlights

  • Q3 revenue booked was £0.2m; new business secured was £0.3m versus £0.1m in Q3 2025.

  • 9M cash operating loss decreased 60% YoY to £4.0m from £9.7m; cash and cash equivalents were £1.4m at 30 September 2026.

  • FY 2026 revenue is expected at ~£1.8m, up 29% YoY from £1.4m in FY 2025; a further £0.1m of business was secured in early October.

Outlook and guidance

  • Q4 investment in growth, product and service optimisation, and new product development is expected to raise average monthly cash expenditure by £0.1m from Q3's £0.4m cash burn.

  • Following receipt of the anticipated £0.8m R&D tax credit, cash runway is expected to extend through Q1 2027.

  • FY 2027 revenue guidance is £3.0m–£4.0m, reflecting anticipated commercial momentum, pipeline expansion and benefits of 2026 operational improvements.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
CelLBxHealth
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ANGLE plc is a British medical diagnostics company focused on developing liquid biopsy solutions for cancer diagnostics. The company’s proprietary Parsortix system enables the capture and analysis of circulating tumor cells (CTCs) from patient blood samples, allowing for non-invasive cancer detection, monitoring, and personalized treatment insights. ANGLE’s technology is used in clinical research and trials, supporting advancements in oncology by providing real-time data on tumor progression and response to therapy. The company is headquartered in Guildford, United Kingdom, and its shares are listed on the London Stock Exchange and the Nasdaq.